Blog

Navigating University Licenses and Industry Collaborations as a Swiss Biotech Startup

Early‑stage biotech companies depend heavily on solid legal foundations, particularly in relation to their core technology. Purposeful negotiation and structuring of license and collaboration agreements can strongly influence...

"Green Marketing": Impact of the new Art. 3 (1)(x) UCA on climate-related advertising

How a new rule in the UCA (Unfair Competition Act) tightens civil and criminal liability for climate-related claims ("green claims").

Totalrevision des Zürcher Gesundheitsgesetzes – ausgewählte Neuerungen für Unternehmende

Einführung

Kaum ein Bereich ist in jüngster Zeit so stark unter Druck geraten wie die Gesundheitsgesetzgebung – von der Bewältigung der COVID-19-Pandemie bis hin zu datenschutzrechtlichen Herausforderungen hinsichtlich...

Stay Compliant When Raising Funds for Your Startup: 8 FAQs

Developing a product or service and scaling a startup's business model need big amounts of cash. Thus, most startups seek capital from investors at some point. There are some legal hurdles to overcome when asking people to invest in your startup.

The BIOSECURE Act: How relevant is it for Swiss biotechnology companies?

The conflict between the USA and China continues to escalate and will probably also have an impact on the biotechnology sector.

Patent Litigation Risk for Pharmaceutical Contract Manufacturers (CMO)

Pharmaceutical contract manufacturers are exposed to the risk of being sued by patent owners. We explain how they can protect themselves from such lawsuits.

Liberalization of the use of Medical Cannabis in Switzerland

The liberalization of Swiss narcotics legislation now allows for easier access to and trade in Medical Cannabis. Dan Pruschy and Stefan Kohler give an overview.

How to determine the conversion price in a convertible note?

In the world of startup financing, a convertible note is an instrument offering several advantages for a startup seeking to raise funds in Switzerland.

Integrity and Transparency for Therapeutic Products – 6 Common Myths

The new provisions on integrity and transparency in the therapeutic products sector have applied since 1.1.2020. Nevertheless, misinterpretations often occur.

Management of Clinical Trials in COVID-19 Times

The management of clinical trials faces major challenges due to COVID-19.